Junhao Liang, Xiaofeng Jiang, Nic Gabriel Reitsam, Tim Lenz, Li Zhang, Marco Gustav, Zunamys Itzell Carrero, Hannah Sophie Muti, Peter Neidlinger, Jan Clusmann, Laura Žigutytė, Vidhya Sainath, Fabian Wolf, Lisa A Boardman, Amy J French, Ellen L Goode, Andrea Gsur, Stefanie Brezina, Marc J Gunter, Robert Steinfelder, Tabitha Harrison, Ulrike Peters, Amanda I Phipps, Philip Quirke, Nicholas P West, Michael Hoffmeister, Hermann Brenner, Durgesh Wankhede, Jitendra Jonnagaddala, Nicholas Hawkins, Robyn L Ward, Elena Fountzilas, Kyriaki Papadopoulou, George Fountzilas, Thierry André, Julien Taieb, Jean-François Emile, Magali Svrcek, Lingjie Kong, Jakob Nikolas Kather
{"title":"Spatial biomarker discovery via interpretable semantic learning in histopathology.","authors":"Junhao Liang, Xiaofeng Jiang, Nic Gabriel Reitsam, Tim Lenz, Li Zhang, Marco Gustav, Zunamys Itzell Carrero, Hannah Sophie Muti, Peter Neidlinger, Jan Clusmann, Laura Žigutytė, Vidhya Sainath, Fabian Wolf, Lisa A Boardman, Amy J French, Ellen L Goode, Andrea Gsur, Stefanie Brezina, Marc J Gunter, Robert Steinfelder, Tabitha Harrison, Ulrike Peters, Amanda I Phipps, Philip Quirke, Nicholas P West, Michael Hoffmeister, Hermann Brenner, Durgesh Wankhede, Jitendra Jonnagaddala, Nicholas Hawkins, Robyn L Ward, Elena Fountzilas, Kyriaki Papadopoulou, George Fountzilas, Thierry André, Julien Taieb, Jean-François Emile, Magali Svrcek, Lingjie Kong, Jakob Nikolas Kather","doi":"10.1016/j.ccell.2026.05.014","DOIUrl":null,"url":null,"abstract":"<p><p>Spatial biomarkers are critical for precision oncology but remain challenging to systematically discover due to the complexity of whole-slide images. We present PathPrism, an interpretable AI framework for spatial biomarker discovery and virtual experimentation. Unlike black-box models, PathPrism encodes tissue architecture into pathologically informed spatial features, enabling transparent modeling of prognosis, molecular alterations, and therapy response. Applied to 7,000 patients with colorectal cancer across 11 cohorts, PathPrism uncovered hundreds of biomarkers predictive of survival, MSI, BRAF, and TP53 mutations, and stratified chemotherapy benefit in stage II/III disease. Building on these interpretable findings, PathPrism uses large language models as auxiliary tools to generate hypotheses grounded in spatial semantics. We further introduce VirtualWSI, a platform for semantic perturbation within an interpretable spatial biomarker atlas. PathPrism provides a scalable and interpretable framework for spatial biomarker discovery.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1605-1622.e7"},"PeriodicalIF":56.1000,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2026.05.014","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Spatial biomarkers are critical for precision oncology but remain challenging to systematically discover due to the complexity of whole-slide images. We present PathPrism, an interpretable AI framework for spatial biomarker discovery and virtual experimentation. Unlike black-box models, PathPrism encodes tissue architecture into pathologically informed spatial features, enabling transparent modeling of prognosis, molecular alterations, and therapy response. Applied to 7,000 patients with colorectal cancer across 11 cohorts, PathPrism uncovered hundreds of biomarkers predictive of survival, MSI, BRAF, and TP53 mutations, and stratified chemotherapy benefit in stage II/III disease. Building on these interpretable findings, PathPrism uses large language models as auxiliary tools to generate hypotheses grounded in spatial semantics. We further introduce VirtualWSI, a platform for semantic perturbation within an interpretable spatial biomarker atlas. PathPrism provides a scalable and interpretable framework for spatial biomarker discovery.
期刊介绍:
Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows:
Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers.
Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice.
Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers.
Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies.
Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.